CLINICAL SIGNIFICANCE OF PROGRAMMED DEATH-1 LIGAND-1 EXPRESSION IN PATIENTS WITH NON-SMALL CELL LUNG CANCER: A 5-YEAR-FOLLOW-UP STUDY

被引：0
|
作者：
Chen, Y-B [1 ]
Mu, C-Y [1 ]
Huang, J-A [1 ]
机构：
[1] Soochow Univ, Affiliated Hosp 1, Dept Resp Med, Suzhou, Peoples R China
来源：
RESPIROLOGY | 2011年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：163 / 163
页数：1
相关论文
共 50 条
  • [21] Assessment of programmed cell death ligand-1 expression with multiple immunohistochemistry antibody clones in non-small cell lung cancer
    Pang, Chen
    Yin, Limei
    Zhou, Xiaojuan
    Lei, Chuanfen
    Tong, Ruizhan
    Huang, Meijuan
    Gong, Youling
    Ding, Zhenyu
    Xue, Jianxin
    Zhu, Jiang
    Wang, Yongsheng
    Ren, Li
    Zhou, Lin
    Wang, Jin
    Peng, Feng
    Zhou, Qiao
    Lu, You
    JOURNAL OF THORACIC DISEASE, 2018, 10 (02) : 816 - 824
  • [22] Programmed Cell Death Ligand 1 Expression in Resected Non-Small Cell Lung Cancer
    Yu, Hui
    Brustugun, Odd Terje
    Ekman, Simon
    Botling, Johan
    La Fleur, Linnea
    Micke, Patrick
    Solberg, Steinar
    Berglund, Anders
    Rivard, Christopher
    Hirsch, Fred R.
    CLINICAL LUNG CANCER, 2021, 22 (04) : E555 - E562
  • [23] Correlation Between Programmed Death-1 (PD-1) Expression in Tumor Infiltrating Lymphocytes and Programmed Death Ligand-1 (PD-L1) Expression in Non-Small Cell Lung Carcinoma
    Driver, Brandon
    Miller, Ross A.
    Deavers, Michael
    Tacha, David
    Bernicker, Eric
    Cagle, Philip T.
    LABORATORY INVESTIGATION, 2017, 97 : 475A - 475A
  • [24] Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer
    Iafolla, Marco A. J.
    Juergens, Rosalyn A.
    FRONTIERS IN ONCOLOGY, 2017, 7
  • [25] Bioinformatics Model of Serum Biomarkers to Prognosticate the Response to Programmed Death-1/Ligand-1 Targeted Immunotherapy in Metastatic Non-Small Cell Lung Cancer
    Tarhoni, Imad
    Multani, Maneet
    Fughhi, Ibtihaj
    Gerard, David
    Fidler, Mary
    Batus, Marta
    Bonomi, Philip
    Borgia, Jeffrey
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2019, 152 : S137 - S137
  • [26] Analysis of soluble programmed death-1 ligand-1 of lung cancer patients with different characteristics
    Zhu, H-B
    Song, X.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2023, 27 (18) : 8690 - 8696
  • [27] Circulating Programmed Death Ligand-1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC)
    Vecchiarelli, S.
    D'Incecco, A.
    Minuti, G.
    Gallo, M.
    De Luca, A.
    Landi, L.
    Bennati, C.
    Spreafico, M.
    D'Arcangelo, M.
    Attilia, L.
    Mazza, V.
    Normanno, N.
    Cappuzzo, F.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2389 - S2389
  • [28] Circulating programmed death ligand-1 (PD-L1) in non-small cell lung cancer (NSCLC)
    Vecchiarelli, S.
    D'Incecco, A.
    Gallo, M.
    De Luca, A.
    Minuti, G.
    Landi, L.
    Bennati, C.
    Spreafico, M.
    D'Arcangelo, M.
    Attilia, L.
    Mazza, V.
    Normanno, N.
    Cappuzzo, F.
    ANNALS OF ONCOLOGY, 2017, 28
  • [29] Programmed death ligand-1 (PD-L1) heterogeneity in non-small cell lung cancer (NSCLC)
    McLaughlin, Joseph
    Schalper, Kurt A.
    Carvajal-Hausdorf, Daniel E.
    Pelekanou, Vasiliki
    Velcheti, Vamsidhar
    Haack, Herbert
    Silver, Matthew R.
    Herbst, Roy
    LoRusso, Patricia
    Rimm, David L.
    CANCER RESEARCH, 2015, 75
  • [30] Comparison of programmed death ligand-1 expression in preoperative transbronchial lung biopsy and resected specimens in non-small cell lung cancer
    Naoko Shigeta
    Shuji Murakami
    Kouji Yamamoto
    Tomoyuki Yokose
    Tetsuya Isaka
    Kota Washimi
    Yohei Miyagi
    Haruhiro Saito
    Hiroyuki Ito
    Aya Saito
    Journal of Cancer Research and Clinical Oncology, 151 (4)
12345